Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of rry tripeptide in preparing medicine for treating Alzheimer's disease

A technology for Alzheimer's disease and drugs, applied in the field of medicine, can solve the problems of unclear drugs for Alzheimer's disease, large drug side effects, and ineffective effects

Inactive Publication Date: 2016-08-17
SUN YAT SEN UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the defects in the prior art that the drug for treating Alzheimer's disease is not clear, the effect is not obvious, and the drug has large side effects, the purpose of the present invention is to provide a drug for preventing and treating Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of rry tripeptide in preparing medicine for treating Alzheimer's disease
  • Use of rry tripeptide in preparing medicine for treating Alzheimer's disease
  • Use of rry tripeptide in preparing medicine for treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental example 1, a kind of Thioflavin T test of RRY tripeptide for preventing or treating Alzheimer's disease:

[0021] Aβ 1-42 Dissolve in pH7.4, the concentration is 0.01mol / L in the phosphate buffer solution of 0.01mol / L and make 50μmol / L mixed solution, Aβ in this mixed solution 1-42 The initial concentration of the peptide was 50 μmol / L, until the final concentration was 2.5 μmol / L, placed at 37 ° C for 48 h, then added ThT (5 μmol / L dissolved in 50 mmol / L glycine-NaOH solution, pH 8.50 ) to detect fluorescence at 450 nm and 485 nm. Each sample was measured 3 times and the fluorescence intensity was recorded.

[0022] combine figure 1 As shown, the results of Example 1 show that: Thioflavin T can rapidly interact with Aβ 1-42 Combined with the polymer fiber, a new light with a wavelength of 450nm is excited, and the light with a wavelength of 482nm is obviously enhanced, while the RRY tripeptide and Aβ 1-42 Co-cultured RRY tripeptide-Aβ 1-42 The thiofl...

experiment example 2

[0023] Experimental example 2, a circular dichroism test of RRY tripeptide for preventing or treating Alzheimer's disease:

[0024] Aβ at a concentration of 50 μmol / L 1-42 Dissolve in phosphate buffer solution, and add RRY tripeptide at a concentration of 50 μmol / L to the experimental group, and then place it at 37°C for 48 h, the Aβ in the mixed solution 1-42 and the final concentration of RRY tripeptide is 5μmol / L, using a container dish with a thickness of 1mm, Aβ 1-42 Monomeric and RRY tripeptide-Aβ 1-42 The complex samples were respectively prevented from detecting the structure in a circular dichroism spectrometer, and the spectra were recorded at 25°C with a wavelength of 190-260 nm and a wave width of 0.5 nm.

[0025] combine figure 2 As shown, the results of Example 2 show that the circular dichroism spectrum shows that the β sheet structure in the RRY tripeptide-Aβ complex will decrease, such as figure 2 As shown, circular dichroism detection of Aβ 1-42 When alo...

experiment example 3

[0026] Experimental example 3, a kind of RRY tripeptide that prevents or treats Alzheimer's disease transmission electron microscope (TEM) test:

[0027] Aβ with phosphate buffer (PBS, pH7.4) 1-42 The sample was dissolved to a concentration of 1 mg / ml, and then placed in the RRY tripeptide experimental group and the blank control group at a concentration of 25 μmol / L, and incubated for 48 hours until the final concentration of the mixed solution was 25 μmol / L, and 5 μl of the sample was applied Add 1% uranyl formate to the 300-hole Formvar-carbon copper grid, stain for 1 min, dry in the air, and then observe under the electron microscope to detect Aβ 1-42 and RRY tripeptide-Aβ 1-42 The structure of the complex.

[0028] combine image 3 Shown, embodiment 3 result shows: as image 3 As shown in the electron microscope image, from Aβ 1-42 Monomer, high-density long linear Aβ can be observed in the figure 1-42 fibers, the fibers aggregate into parallel bundles, and the bu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention requests to protect an application of an RRY tripeptide in preparation of a drug for treating Alzheimer's disease and belongs to the field of medicines. The RRY tripeptide is definite in animal dosage and can be prepared into tablets, microspheres, powders, oral liquids and injections. The RRY tripeptide, when being used in treatment of the Alzheimer's disease, can be used individually and can be used in combination with other Alzheimer's disease drugs in different action mechanisms. When a drug composition composed of the RRY tripeptide, tetrandrine and triptolide is employed in treatment of the Alzheimer's disease, not only are toxic and side effects of the drug reduced, but also a synergistic treatment effect can be achieved. A pharmacologic experiment proves that the RRY tripeptide can effectively inhibit aggregation of A[beta]1-42 and prevent oligomerization of A[beta]1-42 monomer, and can significantly inhibit deposition of [beta] amyloid protein. The RRY tripeptide, when being used for preventing or treating the Alzheimer's disease, is definite in curative effect and is less in side effects so that the RRY tripeptide has a wide medical application prospect.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of a known drug, in particular to the application of RRY tripeptide in the preparation of drugs for treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disorder characterized by short-term memory loss, persistent cognitive decline, and behavioral disturbances. Alzheimer's disease affects a huge number of people around the world, bringing great suffering to people's lives. Now, the exact pathogenesis of AD is still unclear, and it is preliminarily believed to be the joint result of aging, genetic and environmental factors. At present, there are many theories to confirm the exact pathogenesis of AD, among which the most widely accepted amyloid hypothesis is the amyloid hypothesis based on the aggregated and fibril-forming β-amyloid (Aβ) peptide as a biomarker. Aβ is a short peptide consisting of 38 to 42 amino acid res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/06A61P25/28A61K31/585A61K31/4748
Inventor 顾怀宇林润轩段松伟凌楚雯林睿邦黄嘉琦
Owner SUN YAT SEN UNIV